Anosy

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Pharmaceutical, Health, Oncology, San Francisco, Drug development, University, Internal medicine, AbbVie, Stanford University, Oregon Health & Science University, Anosy, Roche, University of California, San Francisco, Cancer, Antibody, Strategic planning, Chugai Pharmaceutical Co., Oregon Health and Science University Center for Women's Health, Patient, UCSF, Physician, Hematology, Protein engineering, Cytokine, Nursing, Genentech

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.
  • In her new role, effective May 1, 2023, she will be responsible for leading Xencor’s clinical and medical strategy and execution.
  • Allen Yang, M.D., Ph.D., Chief Medical Officer, will continue to advise the Company and after a transition period will leave Xencor to pursue other opportunities.
  • “During her time on our Board, Nancy gained a deep understanding of our XmAb® platforms, portfolio strategy, development programs, and people, and we are delighted that she has chosen to join our senior management team,” said Bassil Dahiyat, Ph.D., President and Chief Executive Officer at Xencor.

Xencor Appoints Nancy Valente, M.D., to Board of Directors

Retrieved on: 
Friday, September 9, 2022
Biotechnology, Pharmaceutical, Health, Partnership, University, Security (finance), San Francisco, Roivant Sciences, Cancer, Technology, Chugai Pharmaceutical Co., Form 10-K, Degenerative disease, AbbVie, NASDAQ, Private Securities Litigation Reform Act, Hematology, Ponce Health Sciences University, Hoffmann-La Roche, Oregon Health & Science University, University of California, San Francisco, Internal medicine, Board, Forward-looking statement, Anosy, Cytokine, Board of directors, U.S. Securities and Exchange Commission, Roche, Antibody, Leadership, Biotechnology, Therapy, Stanford University, Oregon Health and Science University Center for Women's Health, UCSF, Annual report, Gesellschaft mit beschränkter Haftung, Patient, Genentech

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to its board of directors.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to its board of directors.
  • We are thrilled to welcome Nancy to our Board, and we look forward to working with her, said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
  • Concurrent with the appointment of Dr. Valente, Xencors Board of Directors accepted the resignation of Yujiro S. Hata, who had served as a director since 2015.
  • Dr. Valente serves on the Boards of Directors of Myovant Sciences GmbH and Immatics N.V. Dr. Valente received her M.D.

Rio Tinto QMM Launches the Construction of Its Renewable Energy Project

Retrieved on: 
Friday, December 10, 2021
Mining, Minerals, Environment, Manufacturing, Alternative Energy, Natural Resources, Energy, Other Manufacturing, Anosy, Climate change, Carbon footprint, QMM, Electricity, Rio Tinto, Government, Maritime, Wind, Industry, CBE, United Nations Environment Programme, Carbon sequestration, PV, Republic, Carbon, Partnership, Civil aviation, Mining, QIT Madagascar Minerals, Renewable energy, Iron ore

The renewable energy project plays a key role in implementing QMM's 'sustainable mine' concept and enabling Rio Tinto operations in Madagascar to reach carbon neutrality by 2023.

Key Points: 
  • The renewable energy project plays a key role in implementing QMM's 'sustainable mine' concept and enabling Rio Tinto operations in Madagascar to reach carbon neutrality by 2023.
  • The renewable energy plant will be built and operated by CBE, a recognized independent power producer, with whom QMM has signed a 20-year power purchase agreement.
  • QIT Madagascar Minerals (QMM), is a joint venture between Rio Tinto (80%) and the government of Madagascar (20%).
  • QMM includes the deep-water Port dEhoala, where the raw material is shipped to the Rio Tinto Fer et Titane plant in Canada and processed into titanium dioxide.

Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors

Retrieved on: 
Monday, November 8, 2021
Audit committee, Female, Sumitomo Dainippon Pharma, Roche, Food, Oregon Health Plan, Growth, Anosy, COVID-19, Pain, University, Review, Uterine fibroid, Gonadotropin-releasing hormone, Pregnancy, Infertility, Oregon, Woman, GLOBE, New Drug Application, Stanford University, Internal medicine, Patient, FDA, Adult, Roivant Sciences, UCSF, Health care, Private Securities Litigation Reform Act, Oregon Health & Science University, San Francisco, Norethisterone, Endometriosis, Twitter, SEC, Texas Health and Science University, United States, Man, Medication, Risk, Senior, University of California, San Francisco, Board, LinkedIn, Breast cancer, NYSE, Leadership, Drug development, Pharmaceutical industry

as an independent member of the companys Board of Directors.

Key Points: 
  • as an independent member of the companys Board of Directors.
  • In addition to her Board appointment, Dr. Valente will chair the Boards Nominating and Corporate Governance Committee and be a member of the Audit Committee.
  • We are excited to welcome Dr. Valente to our Board, said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
  • I am honored to serve on the Board of Directors of Myovant Sciences, said Dr. Valente.